Dr. Einav v Gal-Yam
oncology, breast cancer
oncology, breast cancer
Overview
Country, City
Israel, Ramat Gan
Health facility
SHEBA Medical Center Ramat Gan
Medical unit
Department of breast malignancies
About the doctor
Skills & Expertise
cancer
breast
breast cancer
metastatic breast cancer
endocrine therapy
tumor
capecitabine
palbociclib
chemotherapy
hormone
estrogen
triplenegative breast cancer
esr1
fulvestrant
trastuzumab
petct
oncology
her2negative
lobular breast
breast malignancies
esr1 mutation
solid cancers
68 gafapi
gafapi petct
estrogen receptor
genetics
recurrence breast cancer
lobular breast cancer
receptorpositive breast cancer
malignancies
margetuximab
pembrolizumab
island cancer
cancerous tissues
lasofoxifene monotherapy
silencing tumor suppressor
aromatase inhibitorresistant
infection breast
luminal metastatic breast
petct breast
letrozole hormone
epithelial cells
growth factor
breast tumors
tumor suppressor
ovarian cancer
breast reconstruction
prostate cancer
lung cancer
metastases
Resume
CV (Curriculum Vitae)
Education
- 1993-1996 Bachelor's degree in medical sciences at the Tel-Aviv University
- 1996-2003 Studied human medicine at the Tel-Aviv University
- Obtaining a license for medical practice
- Ph.D. in human genetics at the Tel-Aviv University in Israel
- 2002 Research Assistant at the hemato-oncology lab at the SHEBA Medical Center Ramat Gan
- 2004-2007 Post-Doctoral Scholar at the Norris Cancer Center of the University of Southern California in Los-Angeles
- 2007 Resident at the Department of oncology at the SHEBA Medical Center Ramat Gan
- Obtaining specialization in oncology
- Fellow at the Talpiot excellence and medical leadership program
Experience
- 2002-2003 Medical Intern at the Souraski Medical Center in Tel-Aviv
- Head of the Department of breast malignancies at the SHEBA Medical Center Ramat Gan
- Head of the laboratory of cancer epigenetics at the SHEBA Medical Center Ramat Gan
Languages
English
Hebrew
Publications
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
8 November, 2023
Early Systemic Anti-neoplastic Treatment Post SARS-CoV-2 Infection in Patients with Breast Cancer.
21 October, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
October, 2023
FAQ
Where does the doctor practice?
What is the specialization of Dr. Einav v Gal-Yam?
The primary specialization of the doctor is oncology, breast cancer.
What is the experience of the specialist?
Dr. Einav v Gal-Yam has been practicing for more than 21 years.
Dr. Einav v Gal-Yam
Get individual treatment plan and cost estimate. Non-binding 100% free assessment.
© Dr. Einav v Gal-Yam